Skip to main content

Table 4 Time to index DMT discontinuation: cox proportional hazard models for experienced and naïve DMT users

From: Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

  Experienced DMT Users Naïve DMT Users
  Hazard ratio 95% Confidence interval Hazard ratio 95% Confidence interval
DMT initiated     
 Fingolimod Reference   Reference  
 Interferon beta-1b 2.83 (1.62-4.93) 1.90 (1.25-2.89)
 Intramuscular interferon beta-1a 2.43 (1.49-3.97) 1.53 (1.03-2.28)
 Subcutaneous interferon beta-1a 2.42 (1.54-3.82) 1.58 (1.05-2.38)
 Glatiramer acetate 1.73 (1.11-2.69) 1.53 (1.04-2.24)
Gender     
 Male Reference   Reference  
 Female 1.45 (0.99-2.11) 1.07 (0.89-1.29)
Age categories     
 18-44 Reference   Reference  
 45-54 0.78 (0.55-1.11) 0.81 (0.68-0.98)
 55-64 0.97 (0.65-1.46) 0.75 (0.60-0.94)
 65+ 0.80 (0.38-1.69) 0.67 (0.44-1.01)
Region     
 West Reference   Reference  
 Northeast 0.68 (0.40-1.15) 0.78 (0.60-1.01)
 Midwest 0.99 (0.62-1.59) 0.88 (0.69-1.13)
 South 1.19 (0.75 -1.87) 0.88 (0.69-1.12)
Prior authorization for index prescription 1.21 (0.88-1.65) 1.25 (1.06-1.48)
Copayment for index prescription     
 0-<30 Reference   Reference  
 30-100 0.93 (0.65-1.32) 0.95 (0.78-1.15)
 100+ 0.92 (0.59-1.45) 0.88 (0.70-1.09)
Mail order for index prescription 1.10 (0.59-2.07) 0.57 (0.42-0.78)
Pharmacy type for index prescription     
 Retail Reference   Reference  
 Accredo 1.03 (0.54 -1.97) 1.05 (0.77-1.43)
 Other specialty pharmacy 1.69 (0.86-3.31) 0.78 (0.56-1.07)
  1. Bold numbers indicate that the hazard ratios are significantly different from 1 at p<0.05.